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Abstract
Background: There is an increasing need for complex computational models to
perform in silico experiments as an adjunct to in vitro and in vivo experiments in
immunology. We introduce Microscopic Stochastic Immune System Simulator
(MiStImm), an agent-based simulation tool, that is designed to study the self-nonself
discrimination of the adaptive immune system. MiStImm can simulate some
components of the humoral adaptive immune response, including T cells, B cells,
antibodies, danger signals, interleukins, self cells, foreign antigens, and the interactions
among them. The simulation starts after conception and progresses step by step (in
time) driven by random simulation events. We also have provided tools to visualize and
analyze the output of the simulation program.
Results: As the first application of MiStImm, we simulated two different immune
models, and then we compared performances of them in the mean of self-nonself
discrimination. The first model is a so-called conventional immune model, and the
second model is based on our earlier T-cell model, called “one-signal model”, which is
developed to resolve three important paradoxes of immunology. Our new T-cell model
postulates that a dynamic steady state coupled system is formed through low-affinity
complementary TCR–MHC interactions between T cells and host cells. The new model
implies that a significant fraction of the naive polyclonal T cells is recruited into the first
line of defense against an infection. Simulation experiments using MiStImm have
shown that the computational realization of the new model shows real patterns. For
example, the new model develops immune memory and it does not develop
autoimmune reaction despite the hypothesized, enhanced TCR–MHC interaction
between T cells and self cells. Simulations also demonstrated that our new model gives
better results to overcome a critical primary infection answering the paradox “how can
a tiny fraction of human genome effectively compete with a vastly larger pool of
mutating pathogen DNA?”
Conclusion: The outcomes of our in silico experiments, presented here, are supported
by numerous clinical trial observations from the field of immunotherapy. We hope that
our results will encourage investigations to make in vitro and in vivo experiments
clarifying questions about self-nonself discrimination of the adaptive immune system.
We also hope that MiStImm or some concept in it will be useful to other researchers
who want to implement or compare other immune models.
Keywords: Immune system simulation, Self-nonself discrimination, Self-centered
model, Agent-based model
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Background
We are witnessing a major change in immunology’s conceptual character from an empha-
sis on immunity as a defense to immunity as an interface-of-exchange. Immunity should
be regarded as a communicative system of the internal homeostasis which perceives and
then mediates environmental information (organic and inorganic; internal and external)
[1]. To handle this complexity there is an increasing need for complex computational
models to perform in silico experiments as an adjunct to in vitro and in vivo experiments.
One of the key points of immunity is the concept of self-nonself discrimination. We pro-
posed first that in order to recognize self and non-self, T lymphocytes should recognize
the much smaller set of self antigens, rather than the practically unlimited non-self anti-
gen universe [2, 3]. The immune system is continuously in a state of delicate balance
between tolerating self and attacking non-self. If this balance is perturbed, autoimmune
reactions occur. Immunological tolerance is rooted in regulatory immune cell subsets,
suppressive cytokines, and immune checkpoint pathways [4].
A good example for the delicate balance between immune tolerance and intolerance –
and for the importance of this research area – is the ambiguous results of The Cancer
Immunotherapy Revolution [5], in which the newly approved immunotherapies manipu-
late components of the immune system to attack tumors. Hundreds of clinical trials are
underway to improve responses and success stories of terminal cancer patients defying
the odds and achieving complete remissions are accumulating. Unfortunately, the manip-
ulation of the immune system has also resulted in a major safety issue: the iatrogenic
immune-related adverse events (IrAEs). As a result of the impaired self-tolerance, irAEs
may present with a broad clinical spectrum that mainly involves the gut, skin, endocrine
glands, liver, and lung but can potentially affect any tissue, and their incidence may reach
up to 90% of patients [6, 7].
In order to aid in the qualitative characterization and examination of the delicate
immune balance, we have developed MiStImm computer program, which is capable to
simulate the complex processes of self-nonself discrimination of the adaptive immune
system.We know that a computer model can not reliably simulate the whole immune sys-
tem, however, simulating areas of interest can be useful for testing ideas to help in the
design of in vivo and in vitro experiments [8].
MiStImm uses agent-based modeling technique [9] and it can simulate some aspects of
humoral immune response along with its major components, including T cells, B cells,
antibodies, danger signals, interleukins, self cells and foreign antigens. These simula-
tion components (called “agents”) determine the nodes of a dynamic immune network
where links are the potential interactions between two elements. The immune network
changes step by step (in time) driven by random events. Using the terminology of [10],
a model simulated by MiStimm is an agent-based model that is in part “individual par-
ticle based-stochastic”, and in part “particle number stochastic”. An “individual particle
based stochastic element” is an agent that models individual cells and their individual
random attachments with other cells or molecules. In our program, this approach is used
for Th cells and B cells. A “particle number stochastic element” is a population of cells
or molecules that are represented in the model by the properties of the population and
by the number of elements in it. In our program, this approach is used e.g. for self cells
and foreign antigens. Because our model is stochastic, their attachments with other ele-
ments is also controlled randomly. A great advantage of such a model is that it can easily
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incorporate the most important types of cells and molecules together with their essen-
tial features and simulation events that play important roles in immune reactions. In
such a simulation events – for example interactions of components – occur at random. A
stochastic model fits well with the affinity maturation of B lymphocytes in which random
events are perhaps the most characteristic. It is also suitable to model the development of
the regulatory T cell population and the random selection of specific T cell clones.
To simplify things, we chose the humoral adaptive immune system since the humoral
phase (blood or lymph) may be considered spatially homogeneous; thus a microscopic
spatial volume may represent the whole phase well. A major advantage of this approach
is that it is not necessary to describe the actual spatial positions and spatial motions in
the model. Instead, model components (agents) randomly choose one of the other com-
ponents as interaction partners, because any components are close enough to become
engaged in an interaction.
As the first application of MiStImm, we have simulated two different immune models
and then we have compared performances of them in the mean efficacy of self-nonself
discrimination (see the Results). The first model is called nonself centered orConventional
Role of Self (CRS) where even a primary immune reaction depends on the recognition
of non-self antigens by T and B cell receptors [11–13]. The role of self in this model is
that the great majority of autoreactive T and B cell clones are selected and purged from
the immune system [14]. The second model called self-centered or Enchanced Role of
Self (ERS) which is based on our previously published “one-signal model” [3]. We pro-
posed that model (hypothesis) when we have been seeking the answer to three unresolved
paradoxes of immunology:
• (Q1) How can a tiny fraction of human genome effectively compete with a vastly
larger pool of mutating pathogen DNA [15]?
• (Q2) Considering the fact, that average 3 mutations are formed each of the 1016
times the cell’s 3 · 109 DNA base pairs are duplicated during a human lifetime [16],
“why does cancer occur so infrequently”?
• (Q3) Considering the facts that T cells require three to five days to attain fighting
strength (because they are rare, short-lived, and their doubling time is at least 6 h),
yet how can a T cell response be measurable in the lymph nodes draining the
infection site within 12 to 18 h [17]?
In order to explain these paradoxes, we have suggested a new T cell model [3] that we can
summarize in the following. We have postulated that a dynamic steady state, a so-called
coupled system is formed through low affinity complementary TCR–MHC interactions
between T cells and host cells. Under such condition, it is sufficient to recognize what is
self in order to attack nonself (answer to Q1). We have postulated that the evolutionary
pressure driving the creation of the T cell receptor (TCR) repertoire was primarily the
homeostatic surveillance of the genome (answer to Q2). The new model implies that a
significant fraction of the naive polyclonal T cells is recruited into the first line of defense
from the very outset of an infection (answer to Q3). The computational variant of our
hypothesized T-cell model is the ERS model, presented in this paper. The ERS and CRS
model are summarized by Fig. 1.
Though, there are some immune system simulation models that are capable to simu-
late a conventional (or standard) immune model like our CRS model (e.g. Basic Immune
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Fig. 1 Humoral adaptive immune response by the ERS and CRS model. The ERS model is described by
(a), (b) and (c), while CRS models are described by (c) alone. a In the ERS model, a hypothesized weak affinity
interaction begins in intrauterine life and keeps the immune image of self during the whole life. It is sufficient
for homeostasis; low affinity BCR binds self-antigens and presents self-peptides in their MHCII to regulatory T
helper (Threg) cells; this ensures B and Threg cell survival. b In the ERS model another hypothesized
interaction, intermediate affinity interaction initiate the first line of defense against an infection; some B cells
that have higher BCR affinity for the antigens of the pathogen capture pathogens with intermediate affinity
and present foreign peptides in their MHCII. The foreign peptides indirectly inhibit binding of Threg cells to
these B cells for a critical time period, then the B cells will secrete hypothesized danger signals. Danger
signals activate local Th cells, which in turn, release interleukins that fuel local T cell activation. This way a
non-specific, local polyclonal B and T cell activation is induced, which is the primary defense mechanism
against infections in the ERS model. Clonal expansion requires affinity maturation, which results in a several
magnitude increase of BCR affinity, typically over a time of one week. Randommutations cause the
production of B cells with a broad range of affinities for their presented foreign antigen. B cells with
unfavorable mutations will not get sufficiently activated by the foreign antigen and will die, while those with
improved affinity will be stimulated to clone themselves. c Specific immune reaction, here called as strong
affinity interaction, appears in both the ERS and CRS models and is supervised and supported by pathogen
peptide-specific Th cells, which require direct contact via TCR to the MHCII of the expanding B cell clone.
Such higher affinity interactions would then drive clonal T cell proliferation, activation, lysis of infected cells.
Having cleared the infection, specific T cells could eventually become an expanded memory type T cell
clone, while B cells could differentiate into infection specific antibody-producing plasma cells or memory B
cells. This interaction usually needs several days to efficiently start
Simulator [18], C-ImmSim [19, 20], SIMISYS [21]), they are not directly usable for
modelling the self-nonself discrimination theory of our group (presented by the ERS
model) and compare it with a conventional model. However, when we built MiStImm, we
have adapted some principles of the earlier simulation models (see the Discussion for a
comparison).
The main goal of the simulation experiments of the current paper is showing that the
ERS model matches real patterns and additionally to analyze how the two models (CRS
and ERS) cope against a critical primary infection. That was the main reason why we have
developed MiStImm.
In the Results we show that the ERS model does not develop autoimmune reactions
despite the existence of the hypothesized TCR–MHC interaction between T cells and self
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antigens in the model. Autoimmune reaction is a strong immune response of an organism
against its own healthy cells and tissues. Despite the weak reaction of B and Th cells
against the healthy self cells in the model, the sizes of these self cell populations are not
decreasing, so does not occur a pathological consequence of these weak reactions.
We also show that the ERS model gives better results to overcome a critical primary
infection, answering the paradox “how can a tiny fraction of human genome effectively
compete with a vastly larger pool of mutating pathogen DNA?” We hope that our results
will encourage investigations to make in vitro and in vivo experiments clarifying ques-
tions about self-nonself discrimination of the adaptive immune system.We also hope that
MiStImm or some concept in it will be useful for implementation and/or comparing other
immune models by other researchers.
Implementation
TheMicroscopic Stochastic Immune Simulator (MiStImm) is a single program written in
the C programming language in the spirit of agent-based models [9]. We have provided
its executed binary file for instant use in Windows operation system. It gets its input
parameters from a raw text file. By changing the input parameters new initial conditions
or even new immune models can be set up for the simulation program (see the list of
parameters in Additional file 1). The output of the simulation consists of two text files
containing the state of the system at all time steps with additional statistics. We have also
provided additional tools to visualize and analyze the output of the simulation program.
Components (agents) of the simulation
MiStImm can simulate some components of the humoral adaptive immune system, like
helper T cells, B cells, antibodies, interleukins, self cells, and foreign antigens (Table 1).
Components (agents) are handled as population or individuals and each of them is imple-
mented as a custom data type in C (called “struct” that is similar to a “class” in other
computer languages like C++). Each component has a number of numerical parameters
and certain attached events or processes of events that may occur at random (see details
in Table 1). The output of the simulator contains the number of each components at each
time point so we can trace the changes of the population sizes over a simulation (see sim-
ulation outcomes in the Results). In nature, it is typical that when the size of a certain cell
population gets larger the per capita birth rate in the population decreases. Thus the size
of a population first increases fast, later it slows down, and at the end it gets relatively
stable. So to control birth rates (ensuring that the number of components always remain
in the biologically feasible domain) we have used logistic functions previously applied by
many other authors (see e.g. [22, 23] and Additional file 1).
Progression of simulation events
A simulation progresses with discrete time points by consecutive steps (turns). At each
time point a simulation event is selected randomly from the actual list of the scheduled
events (see possible events in Table 1). Then the selected event occurs and it changes the
state of the system: it can change the state of the simulation components (agents) and also
can include/remove/modify other scheduled events in the list. The random selection (and
the time point of the occurrence) depends on the expected waiting times of the events in
the actual scheduled event list. (See details in the “Mathematical model” section of the
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Table 1 Associated events and behaviors of the simulated components (“agent types”) in MiStImm
program
Agent type Simulation event or behavior Model
Self cell pop. Born ERS/CRS
Foreign antigen pop. Born ERS/CRS
Bone marrow cell pop. Born ERS/CRS
Creates a native B cell ERS/CRS
Creates a T helper cell ERS/CRS
B cell (individual) Born at the periphery by division ERS/CRS
Negative selection in the bone marrow ERS/CRS
Dies because its lifespan terminates ERS/CRS
Emits some danger signals ERS
Activation control process ERS
Action*: ERS/CRS
- detection/killing/antigen presentation ERS/CRS
- division of weak kind ERS
- division of intermediate kind ERS
- division of strong kind ERS/CRS
A plasma cell creates some antibodies ERS/CRS
Th cell (individual) Born at the periphery ERS/CRS
Dies because its lifespan terminates ERS/CRS
Positive and negative selection in the thymus ERS/CRS
Emits some interleukin ERS
Activation control process ERS
Action*: ERS/CRS
- detection ERS/CRS
- division of weak kind ERS
- division of intermediate kind ERS
- division of strong kind ERS/CRS
Danger signal pop. Some danger signals die ERS
Action* ERS
Interleukin pop. Some interleukins die ERS
Action* ERS
Antibody pop. An amount of antibodies dies ERS/CRS
An amount of antibodies acts (kill)* ERS/CRS
B and Th cells are handled individually while the remaining types of agents are handled as population (“pop”.). Each row in the
table describes a scheduled event of the simulation except the subprocesses of the Action events. These subprocesses can occur
along an Action event. Interactions among agents can also occur as an implication of the five action events (signed with an
asterisk*). Some simulation events and subprocess are elements of both the ERS and the CRS model, others are elements only the
ERS model. A plasma cell is a special kind of B cells, a result of a B cell maturity process. A plasma cell has neither a B cell action
event nor a B cell activation control event. On the other hand, it has an antibody birth and an antibody death event. An antibody
has the same shape in the antigen lattice as the BCR of its mother plasma cell
Additional file 1). In the program, each event is implemented as a C function containing
the rules that will be executed when the event occurs (see the details of the rules below
and in Additional file 1). The scheduled simulation event list is programmed as a dynamic
list of individual objects, consisting of the event ID along with its own parameters like the
expected waiting time of the event.
Simulation spaces
The simulation environment of MiStImm is the spatially homogeneous humoral phase
(blood or lymph) of the adaptive immune system. A major advantage of this approach
is that it is not necessary to describe the actual spatial positions (locations) and spatial
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motions in the model. Instead, model components (agents) randomly choose an interac-
tion partner among the other components (agents), because any components are close
enough to become engaged in an interaction. Instead of locations, MiStImm simulates
the spatial shape of the peptides and receptors that are key points of the adaptive immune
response.
Simulation space 1: peptide universe
MiStImm takes a microscopic volume of the humoral phase and also a microscopically
small part of the shape space universe. Shape space models were used by Perelson, Segel
and their colleagues since the 1970’s [24, 25] and also in the Celada–Seiden model [26].
To explain what we mean by shape space here, assume that the shape of a T cell receptor
(TCR) can be represented by a point in a discrete lattice of real numbers. Theoretical
considerations compared with experimental data led to the conclusion that the dimension
of this shape space, i.e. the number of parameters essential in describing a binding, is not
too large, probably around five [24]. The microscopically small part of the shape space
that we consider in the simulation program is a small discrete N × N planar grid in the
shape space (default: N = 1000). The x ∈ {0, 1, . . . ,N} coordinate of a shape point may
represent a “horizontal” coordinate of the main part of the binding profile of a TCR or
an MHC+peptide complex, while the y ∈ {−N/2, . . . ,N/2} coordinate may represent
the “vertical” coordinate of the main part of the binding profile. A positive coordinate
represents “convexity”, while a negative coordinate represents “concavity”. Figure 2a shows
our underlying idea for the shape of a peptide characterized by a single point (xP, yP). We
call the above finite square grid the peptide lattice.
Simulation space 2: antigen universe
The shape of a B cell receptor (BCR) or shape of an antigen is similarly represented by
a point of an antigen lattice in the model. Here again the x ∈ {0, 1, . . . ,N} coordinate of
a shape point may represent a “horizontal” coordinate of the main part of the binding
profile of the BCR or antigen, while the y ∈ {−N/2, . . . ,N/2} coordinate may represent
the “vertical” coordinate of the main part of the binding profile; a positive coordinate
representing “convexity”, while a negative coordinate representing “concavity”, see Fig. 2a.
Interactions of agents in simulation
Complementarity of binding
Complementarity plays a basic role in binding. The perfect fit between a TCR and an
MHC+peptide complex means in the model that the shape (xT , yT ) of the TCR and
the shape (xP, yP) of the MHC+peptide satisfy the equalities xT = xP and yT = −yP,
see Fig. 2a. In the model we introduce a metric or distance d to measure the degree of
similarity of two shapes z1 := (x1, y1) and z2 := (x2, y2):
d(z1, z2) := max{|x2 − x1|, |y2 − y1|}. (1)
(This is called the maximum or ∞ distance in mathematics.) A TCR zT := (xT , yT ) and
an MHC+peptide zP := (xP, yP) are perfectly complementary in our model if the dis-
tance between zT and zP := (xP,−yP) is zero. The larger the distance, the more imperfect
the complementarity is. The representation of the complementarity between BCRs and
antigens is similar. Only complementary or nearly complementary shaped ligands and
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Fig. 2 a Two simplified complementary shapes characterized by the points (xP , yP) and (xP ,−yP),
respectively, in the peptide lattice. b Simplified graphical representation of the difference between the ERS
and the CRS models. Dark blue: area allocated to regulatory T cells; Green: area for potential infection specific
T cells; Intensity of the colors represent the density of T cells in the area (a darker color means larger density)
receptors can bind. The dots in Fig. 2b represent TCRs that are exactly complementary to
some self MHC+self-peptide complex. In the case of ERS model, the areas shaded in dark
blue are called the characteristic rings of self-peptides. They represent the set of shapes
that are allocated to possible regulatory T cells after negative and positive selection in
the ERS model. The areas denoted by green correspond to possible shapes of classical,
potentially infection (or mutation) specific T cells, while white areas are representing self-
reactive T cells that are prohibited for T cells in the two respective models. In the ERS
model, moderately self-reactive T cells are present after negative and positive selection. In
fact, they constitute the most important class of T cells that decide self-nonself discrim-
ination. On the other hand, such moderately self-reactive T cells are negatively selected
out in CRS models.
Interactions among agents are implications of the following simulation events: T cell
action, B cell action, danger signal action, interleukin action, antibody action (see events
signed by asterisks in Table 1). These interactions are realized as BCR – antigen binding,
TCR –MHC+peptide binding, or danger signals/interleukins emission (for details see the
“Complementarity of binding” section above and Additional file 1). In MiStImm, T cell –
B cell interactions are basic, here we describe three different types of it. Each of the three
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types fulfills an important role in the ERS model (Fig. 1). CRS model can be described by
the third type of interactions (called strong interaction and division) alone.
Weak affinity interaction and division (specific to ERSmodel)
According to the hypotheses of ERS model, in a healthy individual during intrauterine
life, randomly produced moderately self-reactive B cell clones are confronted with an
overwhelming quantity of soluble self antigens. Those B cells that can attach with inter-
mediate affinity to any of these self antigens via their B cell receptors (BCRs) will present
self peptides in their surface major histocompatibility complex II (MHCII) molecules to
regulatory T helper cells (Thregs). This ensures B cell and Threg cell survival, respec-
tively, but it is insufficient to trigger extensive clonally based B cell expansion required for
specific immunity or autoimmunity. This hypothesized interaction is called weak affinity
interaction and division here. Thus the positively selected Threg cells are critical parts of
the homeostatic control in our model so that Threg clones exist for practically all kinds
of self-MHCII – self-peptide complexes presented by any of the B cells. After birth, this
process maintains an immune image of soluble self which can control self-nonself dis-
crimination. This self-surveillance makes ERS model self-centered (rather than infection
centered) and gives the answer to the Q2 paradox mentioned in the “Introduction”.
Intermediate affinity interaction and division (specific to ERSmodel)
During a primary infection a new antigen appears in the blood. B cells with an appropriate
affinity for the new antigen, engulf new antigens and present its foreign peptides on their
surface MHCII proteins. Since in the ERS model foreign peptides temporarily inhibit the
complementary TCR-MHC interactions, such perturbation creates steric hindrance that
obstructs the docking of positively selected Thregs. Disruption of such contact between
an MHCII and Thregs for a critical period of time results in an emergency and activates
the corresponding B cell. In order to reestablish contact, in the ERS model, foreign pep-
tide presenting B cells will secrete a hypothetic chemotactic danger signals (“smoking gun”)
attracting Th cells to this region. We imagine this process as the B7-1 and B7-2 ligands
of B cells will activate most CD28 receptors of the bystander helper T cells, This initi-
ates a non-specific, polyclonal activation in local Th lymphocytes via the CD28 receptor
alone [27] such that a local cytokine storm is generated in Th cells triggering B cells to
clonal expansion, hypermutation, and eventually they may develop into specific antibody-
producing plasma cells. This hypothesized interaction will be called intermediate affinity
interaction and division here. The resulting inner state of the affected Th and B cells
will be called “activated” state. Since affinity maturation is driven by the fast increasing
local concentration of pathogen antigens (e.g. hepatitis virus), the probability of clonal
autoimmunity is very low but possible.
Strong affinity interaction and division (specific to both ERS and CRSmodel)
Both in ERS and CRS model, following the initial polyclonal activation phase, there is
always a possibility that rare T cell and B cell clones with higher affinity may well rec-
ognize foreign antigens, particularly when a significant fraction of host cells are infected
and the viral load is high (for example in hepatitis, see in [28]). Such higher affinity inter-
actions would then drive clonal (e.g. HCV specific) T cell proliferation, activation, lysis of
infected cells. Having cleared the infection, specific T cells could eventually become an
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expanded memory type T cell clone, while B cells could differentiate into infection spe-
cific antibody-producing plasma cells or memory B cells. Specific T and B cell activation,
proliferation and lysis of infected cells, therefore, obey the rules of the conventional two-
signal model. Clearly, this process may require several days in general. This interaction
will be called strong interaction and division in the sequel. The resulting inner state of the
affected Th and B cells is called “strongly activated” state here.
Hypothesized danger signals and interleukins (specific to ERSmodel)
We use the symbolic names “danger signals and interleukins” in this paper, without spec-
ifying the exact type of these molecules, similarly to Fig. 3 of Ref. [29]. These types of
soluble molecules have roles only in intermediate interactions and divisions in the ERS
model. Since conventional immune reactions correspond to the ones that we call strong
interactions and divisions, these types of molecules do not appear when simulating CRS
models. Danger signals (soluble molecules) are emitted by B lymphocytes following dis-
ruption of the homeostatic complementary interaction of B cells and Threg cells. This
event initiates an action event and also a death event of these molecules. Each danger
molecule randomly chooses a Th cell agent. This is a signal for the Th cell to start inter-
mediate type division and to secrete interleukins. Note that this danger signal is not the
same as in [30] because our danger signals are emitted when the system detects any kind
of nonself and not only a dangerous one. Interleukins are emitted by Th lymphocytes.
This event initiates an action event and also a death event of these interleukins. Each
interleukin molecule randomly chooses a B cell. This is a signal for a B cell that has lost
complementary Threg cell control to start cell division of intermediate kind. For more
details of interactions see in the Additional file 1.
Parameter setting, model validation
MiStImm can be initialized by 178 of parameters (see Additional file 1). The simulation
program, along with its parameter values, was developed by trial and error comparing
the simulation outcome patterns to the normal behavior observed in living systems. For
example, we set the parameters so that the number of T cells and the number of B cells
be approximately equal during a simulation, or we have used logistic functions to prevent
population explosion of the components (see details in the Additional file 1). We also
used some principles that were tested by other researchers in their work (see Discussion).
Simulation outcomes demonstrating our endeavors are shown in the Results.
Limitations and future perspectives
MiStImm can be easily customized by varying parameters. However, model that is
remarkable different from the default settings of MiStImm could be difficult to imple-
ment because it requires understanding of the source code written in C. For example, it is
easy to vary the type and initial number of foreign and self cells (and many another input
parameters), but it is relatively hard to implement a new type of cells (like macrophages)
or change the binding model. To solve this limitation an implementation of a Python
library would be beneficial providing an easy-to-use interface to customize an immune
model from built-in building blocks (similarly as Keras librarymakes deep learning as easy
as manipulating LEGO bricks [31]). We think such a big enterprise could revolutionize
immune system modelling. MiStImm is one of the first steps in that road.
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Results
Simulations of the ERS model show real patterns
Beside providing screenshots of MiStImm simulation tool, the following simulation
results demonstrate that the ERS model – introduced above – show real patterns. For
example, the ERS model does not develop autoimmune reactions despite the hypoth-
esized enhanced TCR–MHC interaction between T cells and self antigens. We also
perform in silico experiments to show the existence of immunememory in the ERSmodel,
and we also show an example of autoimmune reaction at given pathological conditions.
Simulation of the development and homeostasis of the adaptive immune system by the
ERS model
We have run simulation experiments for the analysis of the development and homeostasis
of the simulated immune system by the ERS model. A simulation starts a few days after
conception and goes until the 5000th time step; the unit of time is being a tenth of a day
(2 h and 24min). Initially, only three types of non-immune self antigen populations appear
in the model, each with a number of 150 cells, and no other components. Each of these
populations is accompanied by a cell division process that implies continuous growing
of the number of self cells, with decreasing rate in time (Fig. 3a). B and T cells, which
generated by the bone marrow cells, first appear at the 10th day (Fig. 3b). The number
of these cells also grow continuously at a decreasing rate. According to the ERS model,
the immune system does not attack self cells strongly, just to a very limited extent. Some
B cells must continuously present self peptides to ensure that Threg cell characteristic
rings around self peptides are constantly maintained. Because of negative selection, this
type of immune response is weak and typically settles down quickly before it becomes
pathological.
The peptide and the antigen lattices both have has a size {0, 1000}× {−500, 500}. Coor-
dinates of antigens of three different self cells (denoted by letters “s”) were (550, 300),
(700,−200) and (850, 150), both in the case of the peptide and the antigen lattice (Fig. 4a
and b). TCR rings around the mirror images of self peptides – that are characteristic fea-
tures of the ERS model – begin to develop about the 150th day and become more or
less stabilized by the 280th day (Fig. 4a). These rings fluctuate for two reasons: (i) occa-
sionally global Th cell populations overgrow the set upper limits and this reduces the
Fig. 3 Simulation of the development and homeostasis of the adaptive immune system by the ERS model.
The same single simulation in a bird’s eye view (a) and a closer view (b), respectively. Horizontal axis: time
(day) from conception. Vertical axis: number of cells/molecules. In the case of self cells the sum of sizes of the
self cell populations is displayed
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Fig. 4 Simulation spaces (peptide and antigen lattices) in the ERS model. a A snapshot of the peptide lattice,
where the actual TCRs are displayed. With random ‘rings’ around the reflected images of non-immune self
antigens (“s”) about one month after birth. A movie capturing a typical simulation of the peptide space is
available at the address https://goo.gl/QcdG48. b A snapshot of the antigen lattice, where the actually
existing BCRs are displayed. B cell response to a pathogen: large density of pathogen specific B cells at the
reflected image of nonself (“n”) about one week after the infection. As a result of negative selection, there are
empty domains around the reflected images of non-immune self antigens (‘s’). A movie capturing a typical
simulation of the antigen lattice (shape space) is also available at the address https://goo.gl/3oK1bM
probability of Th cell division; (ii) sometimes the number of presented self peptides in the
MHCII-peptide complexes of B cells reaches an extremely low level.
Simulations of the normal immune response and immunememory by ERS model
We have run simulations with the same parameters as above in the development and
homeostasis section with the exception that we have injected pathogens into the system
at two distinct time points. An infection brings significant changes. A rising population
of B and Th cells appear at the mirror image of the infecting agent denoted by a let-
ter “n” (Fig. 4b). An immune response should have the ability to destroy the majority of
pathogens – some of them suddenly, others perhaps slowly, while in some cases it may fail.
In the ERS model, the death of an individual occurs when the pathogen population grows
up irreversibly, technically, as its size reaches 4000 cells. Diversity of pathogens are repre-
sented by different locations of their receptors, different speeds of growth, and different
initial numbers.
A normal immune response develops immune memory. Thanks to memory cells, a sec-
ond immune response against the same nonself antigen have been more effective than at
a primary infection (Fig. 5a and b). For a deeper analysis of the immune memory, we have
performed 500 simulations (by the ERS model), adding the same type of pathogen (num-
ber of cells = 350, mean waiting time between two divisions = 60) at the 300th and at
the 315th day. ERS model cleared both infections in 451 cases and the mean time lengths
needed for elimination were 62.02 (std 13.26) at the first infection and 20.51 (std 14.94)
at the second infection. We have said that an elimination happened when the number of
pathogens has decreased under 50. With a two-tailed t-test, the p-value for equality of
mean elimination times for the first and the second infection was 5.2e − 227.
Simulation experiment with lack of negative selection of B cells in the ERS model
We want to demonstrate that our simulation tool is capable to simulate autoimmune
events at given pathological conditions, for example, the lack of negative selection of B
Kerepesi et al. Theoretical Biology andMedical Modelling            (2019) 16:9 Page 13 of 20
Fig. 5 Immune response in the ERS model. a Normal immune response against a repeated infection. First
infection was injected at the 300th day and the second infection was injected at the 310th day. Both
infections are the same type (number of cells = 350, mean waiting time between two divisions = 60). The
second infection was eliminated faster due to the existence of B cell memory. Horizontal axis: time (day) from
conception. Vertical axis: number of cells/molecules. b Division of weak/intermediate/strong kind of T and B
cells in the same simulation showed in (a). Horizontal axis: time (day) from conception. Vertical axis: number
of divisions. c Autoimmunity caused by the lack of negative selection of B cells: number of self cells decreases
rapidly. Horizontal axis: time (day) from conception. Vertical axis: number of cells/molecules
cells is shown in Fig. 5c. Without negative selection some of the B cells can constantly
destroy self cells.
Simulation experiments for comparison of ERS and CRSmodel against a critical infection
One can switch the ERS (Enhanced Role of Self ) model to a CRS (Conventional Role of
Self ) model by modifying four parameters. Turning off the division of weak type and
the division of intermediate type are required in the CRS model (medrepr = 1 → 0
and weakrepr = 1 → 0). Turning off the positive selection of T cells is also required
in the CRS model (comptype = 0 → 1). The latter adjustment causes large growth
of the T cell population, so simultaneously we need to decrease the expectation of
the waiting time between two births of T helper cells in the bone marrow (tauthm
= 5 → 30). We compared the efficiencies of the immune reactions in the two mod-
els. Our results showed that in the ERS model the adaptive immune reaction was able
to destroy infections with critically large initial numbers or with critically fast divi-
sion times more often than in a CRS model (Tables 2 and 3). Fisher’s exact test was
used for the statistical evaluation (Table 4). These results show that our ERS model is
a proper answer to the paradox Q1, mentioned the Introduction, saying “How can a
tiny fraction of human genome effectively compete with a vastly larger pool of mutating
pathogen DNA”.
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Table 2 ERS vs. CRS model, simulated by MiStImm 500–500 times as the initial number of pathogens
is increasing (from 200 to 400) and the mean waiting time between two divisions of a pathogen is
fixed (50)
f cells div time ERS wins CRS wins ratio p-value
200 50 499 432 1.155 1.1E-20
250 50 497 361 1.377 1.85E-42
300 50 481 310 1.552 5.19E-45
350 50 417 225 1.853 4.48E-38
400 50 272 135 2.015 5.74E-19
The table shows how the performance of ERS and CRS model is changing when we increase the initial number of pathogens. The
unit of time is one-tenth of a day; f cells: the initial number of foreign cells at the 300th day; div time: the mean waiting time
between two divisions of a foreign cell; ERS wins: number of wins of the immune system against pathogens using the ERS model
setting; CRS wins: number of wins of the immune system against pathogens using the CRS model setting; ratio: ERS wins divided
per CRS wins; p-value: one-sided p-value of the Fisher’s exact test. In every case ERS performed significantly better than CRS
Sensitivity analysis of the model parameters
The objective of a sensitivity analysis (SA) is to identify critical input parameters of
a model and quantifying how input uncertainty impacts model outputs [32]. In the
previous section, we investigated how a given output (win or lose against a critical infec-
tion) changes when we vary one particular input parameter. In this section, we investigate
how output variables change when we vary more than one input parameters randomly at
the same time. This method gives a more global insight into the correlations between the
input and output.
For this purpose, we have chosen 13 critical parameters that we have sampled randomly
(by uniform distribution) around its default value (Table 5). The remaining parameters
have been fixed (to the same values as in Fig. 5a and b). We have also varied the ran-
dom seed of the simulations, as usual. Each simulation was stopped at the 305th day (5
days after an initial infection) and the output variables were only evaluated at the end of
the simulation (see Additional file 2 for the raw data of the 500 simulations). Our main
observations are summarized in Fig. 6, which shows the distributions of the output val-
ues Fig. 6a, and the correlations between input values and output values Fig. 6b, c and d.
Interestingly, most of the input parameters do not correlate with any of the other output
variables.We can suppose that this trendwould remain if we would analyze all of the input
parameters. So, actually, there may be much more unimportant (or even unnecessary)
input parameters.
Another interesting observation is that the largest correlation is between the input
parameter r0 (action radius of naive B cells) and nW (number of self cells). This may be
Table 3 ERS vs. CRS model, simulated by MiStImm 500–500 times as the mean waiting time
between two divisions of a pathogen is increasing (from 40 to 80) and the initial number of
pathogens is fixed (350)
div time f cells ERS wins CRS wins ratio p-value
40 350 208 66 3.152 1.19E-24
50 350 417 225 1.853 4.48E-38
60 350 473 320 1.478 1.16E-35
70 350 493 400 1.233 1.42E-24
80 350 500 441 1.134 2.81E-19
The table shows how the performance of ERS and CRS model is changing when we increase the mean waiting time between two
divisions of a pathogen. Column labels are the same as in Table 2 but the positions of the columns “f cells” and “div time” are
switched. In every cases ERS performed significantly better than CRS
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Table 4 Contingency table of the one sided Fisher’s exact test [54] for the fourth row of Table 2, as
an example
ERS CRS Row total
Win 417 225 642
Loss 83 275 358
Col total 500 500 1000











) ≈ 4.48E − 38. Note that the values of the
hypergeometric distribution inside the sum are the probabilities of choosing 500 experiments out of 1000, containing exactly i ERS
wins of the given 642 total number of wins and also choosing exactly 500 − i ERS losses of the given 358 total number of losses
due to the main characteristic of our proposedmodel (ERSmodel) that enables a constant
weak connection between B cells and self cells. As we increase the radius of naive B cells
there will be more reachable self peptides for naive B cells and it turns into a catastrophe,
actually, an autoimmune reaction. The conclusion is that if we want to simulate a healthy
(normal) immune reaction we must not set r0 to a value larger than 150 (see Fig. 6c). The
second largest correlation was observed between the input parameter taub0 (mean wait-
ing time between two actions of a B cell) and the output value nR (number of foreign
cells). This means, not surprisingly, that the more the B cells action, the more efficient the
immune reaction is.
Discussion
When we built our simulator tool MiStImm, we have used some principles that were
tested by other researchers in their work. The earliest related computer simulation model
is the cellular automaton model Celada and Seiden [8], which is focused, similarly as
MiStImm, on the processes that are important for the initiation and regulation of the
humoral immune response. All entities (A cells, B cells, T cells, antigens, antibodies)
of the Celada-Seiden model along their structural elements appear in MiStImm (except
the A-cells), however, we used a more complex model of affinity maturation. Another
closely related model is an agent-based model, the C-IMMSIM [19, 20]. The main dif-
ferences between C-ImmSim and MiStimm are that C-Immsim represents pathogens
Table 5 Input parameters for sensitivity analysis
Parameter Type Default Min Max
r0 int 150 50 250
pmem float 0.3 0.1 0.5
crnew float 0.9 0.1 1.7
rminnew int 5 1 9
crspread float 0.9 0.1 1.7
rminsprd int 5 1 10
thrad int 80 50 250
pmut float 0.4 0.1 0.7
taub0 float 5 1 9
tauth0 float 2 1 9
tcrit_stress float 2 1 3
nr int 350 200 500
tr float 60 40 80
Values were sampled randomly with uniform distribution around its default value (between Min and Max). Borders of the ranges
were chosen rather intuitively, appropriate to the meaning of the parameters, with the rule that the default value should be in the
middle of the range
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Fig. 6 Sensitivity analysis to investigate how 13 critical input parameters impact certain output values 5 days
after a random type of infection. a Value distribution of the input parameters b Pearson correlation
coefficient between input parameters (horizontal axis) and output variables (vertical axis). Values are rounded
to one decimal. c Scatter plot of the input parameter r0 (action radius of naive B cells) and the output variable
nW (number of self cells). d Scatter plot of the input parameter taub0 (mean waiting time between two
actions of a B cell) and the output variable nR (number of foreign cells). Descriptions of the output variables:
nW, no. selfs; nR, no. foreign cells; nB, no. B cells; nAb, no. antibodies; nTh, no. T cells; nIL, no. danger signals;
nM, no. bone marrow cells. Description of input parameters: see Table 1 in Additional file 1 or the file “indat1”
in the Github repository of MiStImm
and lymphocytes receptors by their amino acid sequences and use bioinformatics meth-
ods for T and B cell epitope prediction. The Basic Immune Simulator (BIS) [18] is also
a closely related agent-based computing model that is intended to study the interac-
tions between innate and adaptive immunity and demonstrated that the initial innate
response is crucial for an appropriate adaptive response. [21] developed SIMISYS, which
is also a cellular automata model of the human immune system. It uses tens of thousands
of cells and innate and adaptive components of the immune system. In particular, the
model contains macrophages, dendritic cells, neutrophils, natural killer cells, B cells, T
helper cells, complement proteins, and pathogenic bacteria. Reference [33] investigates
a hypothesis about B cell hypermutation and affinity maturation using both individual
particle-based stochastic and concentration-based non-spatial non-stochastic, ordinary
differential equation models. A B cell model developed in [34] has partly similar ideas
as our B cell model, but differs from MiStImm in the representation of ligands that are
encoded by bit strings and their distances are measured by the number of mismatches
(Hamming distance) (like in the above-mentioned IMMSIM and C-ImmSim models).
Similar (but not identical) to our ERS model is the mathematical model of T cell medi-
ated suppression of [35], where tolerance is also based on ubiquitous and constitutive
self-antigens, which select and sustain clones of specific regulatory (R) cells, and which
are similar to our Treg cells. In their model, R cell populations represent typically between
30% and 95% of the total T cells in the periphery. It is an important difference to the widely
accepted view in which conventional regulatory CD4+CD25+ T cells (Treg) usually make
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up only about 5–10% of CD4+ T cells [36]. R cells perform their function through linked
recognition of the APCs (antigen presenting cells). Also in theirmodel, immune responses
to foreign antigens are achieved by displacing the self-antigens from the APCs, leading to
a loss of R cells if the foreign antigen introduction entails a sharp increase in the number
of foreign antigen carrying APCs.
Predictions of our theoretical model and the outcomes of the in silico experiment of the
Results are supported by numerous clinical trial observations. As a result of the cancer
immunotherapy revolution hundreds of clinical trials of the newly approved immunother-
apies are now under way to improve responses. Not unexpectedly, the 2018 Nobel Prize
in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo for their
development of cancer therapy by blockade of co-inhibitory signals. While success sto-
ries of terminal cancer patients achieving complete remissions are accumulating, not
enough research has been done into the risks of the new therapies. The developers of
the inhibitory anti-CTLA-4 antibody started with the premise that a CTLA-4 (cytotoxic
T lymphocyte-associated antigen 4) blockade would selectively target anti-tumor T cells
[37]. Although the anti-CTLA-4 antibody improved survival in a minority of metastatic
melanoma patients, the vast majority suffered autoimmune-related adverse events (irAEs)
[38]. While the conventional nonself centered T cell activation models (implemented as
the CRS model in MiStImm) are unable to explain the widespread and dose-dependent
irAEs, our self-centered T cell activation model (implemented as the ERS model in
MiStImm) can [2, 3]. The reason for this that the nonself-centered models eliminate self-
reactive immune cells to ensure that an activation signal can exclusively originate from a
foreign/mutated antigen. However, there is evidence for that immune cells require cog-
nate receptor engagement with ubiquitous self antigens in their ’flight for survival’ [39].
During such engagements T cells receive ’tonic’ signal one (TCR signal) generated by
positively selecting self-peptide/MHC, which promotes activation and homeostatic sur-
vival of T cells in the periphery (see regulatory T cells of the ERS model in MiStImm).
Furthermore, there is evidence for control of such tonic TCR signals by co-inhibitors
[40]. This is consistent with a critical role for co-inhibitors early in life to establish toler-
ance in the first T cells that seed the periphery ([40–42]. In addition, the ability of TCRs
to interact with tonic self-peptide/MHC ligands opens the possibility that co-inhibitor
blockade causes T cell effector activity to spill over onto nearby healthy cells. Increased
collateral damage is indeed seen during immune responses where a co-inhibitor is lack-
ing [43]. Altogether, the above concepts suggest that all T cells are temporarily activated,
expressing co-inhibitors such as CTLA-4 that can then be targeted by anti-CTLA-4 anti-
bodies. This is consistent with the immunological homunculus concept of Irun Cohen,
who suggested that the immune system continuously responds to self [44]. Prolonged
therapeutic overstimulation of T cells by antibodies that target their negative regulators
(immune checkpoint, IC) such as CTLA-4 and the programmed cell death protein 1 path-
way (PD-1/PD-L1) led to a breakthrough in the treatment of a variety of malignancies.
While three generations of IC immunotherapy have been developed since Ref. [45, 46],
the safety of IC blockade is still an unresolved, timely and sensitive issue in the context
of advanced cancer patients. By now Science has acknowledged that these patients are
“human experiments” of the autoimmune process [47]. Notwithstanding, we could not
find a paper (other than our own) that deduced the widespread irAEs based on the sim-
ilar outcomes of the TGN1412 and ipilimumab trials despite the fact that the number
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of ipilimumab papers has increased from 144 (in 2011) to 2585 (PubMed search as of
October, 2018). As a result of the impaired self-tolerance, irAEs may present with a broad
clinical spectrum that mainly involves the gut, skin, endocrine glands, liver, and lung but
can potentially affect any tissue, and their incidencemay reach up to 90% of patients [6, 7].
Actually, theNobel committee emphasized that a crucial aspect in the future development
of checkpoint inhibitor therapies is to improve understanding of events leading to adverse
events.1 Since the use of immunotherapy is becoming more common, and is expected
to develop into first- and second-line treatments, immunotoxicity and autoimmunity
are emerging as the nemesis of immunotherapy. Based on our self-centered theory, we
have addressed the controversy regarding the safety–efficacy issue in immunotherapy
trials and argued that the price we pay for reversing immunosuppression in cancer by
a prolonged immune checkpoint blockade is the generation of uncontrolled T-cell acti-
vation [48–51]. We predicted that harnessing the unleashed autoimmune power of T
cells by low dose IC blockade could be rewarding to defeat cancer. Using our prediction,
Ref. [52, 53] have developed just such a promising combination therapy, which was safely
and successfully administered to heavily pretreated stage IV cancer patients who had
exhausted all conventional treatments.
Conclusions
We described the MiStImm simulation tool that was made to investigate some impor-
tant characteristics of immune development, starting from conception and ending some
time after birth. Results of some computer experiments were discussed. An impor-
tant part of the latter was the comparison of the CRS and ERS theoretical models.
We think that it is likely that evolution preferred adaptive immune systems whose
basic mechanism is closer to the ERS model than to a CRS model because ERS gives
better results to overcome a critical primary infection. We hope that our ideas and
our computational model may encourage investigations about the problems raised in
this paper, using both in vitro and in vivo experiments. We would especially like to
see experiments clarifying questions about self-nonself discrimination in a primary
infection.
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